Characteristic | Total (cases) | Blood four-type group [cases (%)] | P | Blood two-type group [cases (%)] | P | ||||
---|---|---|---|---|---|---|---|---|---|
O | A | B | AB | O | Non-O | ||||
Total | 697 | 255 | 195 | 188 | 59 | Â | 255 | 442 | Â |
Age (years) | Â | Â | Â | Â | Â | 0.313 | Â | Â | 0.722 |
 ≤60 | 597 | 220 (86.3) | 162 (83.1) | 167 (88.8) | 48 (81.4) |  | 220 (86.3) | 377 (85.3) |  |
 >60 | 100 | 35 (13.7) | 33 (16.9) | 21 (11.2) | 11 (18.6) |  | 35 (13.7) | 65 (14.7) |  |
Gender | Â | Â | Â | Â | Â | 0.854 | Â | Â | 0.730 |
 Male | 492 | 178 (69.8) | 137 (70.3) | 137 (72.9) | 40 (67.8) |  | 178 (69.8) | 314 (71.0) |  |
 Female | 205 | 77 (30.2) | 58 (29.7) | 51 (27.1) | 19 (32.2) |  | 77 (30.2) | 128 (29.0) |  |
ECOG PS | Â | Â | Â | Â | Â | 0.960 | Â | Â | 0.911 |
 0–1 | 680 | 249 (97.6) | 190 (97.4) | 184 (97.9) | 57 (96.6) |  | 249 (97.6) | 431 (97.5) |  |
 ≥2 | 17 | 6 (2.4) | 5 (2.6) | 4 (2.1) | 2 (3.4) |  | 6 (2.4) | 11 (2.5) |  |
B symptoms | Â | Â | Â | Â | Â | 0.295 | Â | Â | 0.133 |
 Yes | 324 | 109 (42.7) | 101 (51.8) | 86 (45.7) | 28 (47.5) |  | 109 (42.7) | 215 (48.6) |  |
 No | 373 | 146 (57.3) | 94 (48.2) | 102 (54.3) | 31 (52.5) |  | 146 (57.3) | 227 (51.4) |  |
LDH (U/L) | Â | Â | Â | Â | Â | 0.596 | Â | Â | 0.602 |
 >245 | 194 | 68 (26.7) | 53 (27.2) | 59 (31.4) | 14 (23.7) |  | 68 (26.7) | 126 (28.5) |  |
 ≤245 | 503 | 187 (73.3) | 142 (72.8) | 129 (68.6) | 45 (76.3) |  | 187 (73.3) | 316 (71.5) |  |
Tumor size (cm) | Â | Â | Â | Â | Â | 0.399 | Â | Â | 0.953 |
 ≥5 | 65 | 24 (9.4) | 21 (10.8) | 18 (9.6) | 2 (3.4) |  | 24 (9.4) | 41 (9.3) |  |
 <5 | 632 | 231 (90.6) | 174 (89.2) | 170 (90.4) | 57 (96.6) |  | 231 (90.6) | 401 (90.7) |  |
Extranodal sites ≥2 |  |  |  |  |  | 0.685 |  |  | 0.966 |
 Yes | 77 | 28 (11.0) | 22 (11.3) | 18 (9.6) | 9 (15.3) |  | 28 (11.0) | 49 (11.1) |  |
 No | 620 | 227 (89.0) | 173 (88.7) | 170 (90.4) | 50 (84.7) |  | 227 (89.0) | 393 (88.9) |  |
Regional LN involvement | Â | Â | Â | Â | Â | 0.605 | Â | Â | 0.239 |
 Yes | 171 | 69 (27.1) | 42 (21.5) | 46 (24.5) | 14 (23.7) |  | 69 (27.1) | 102 (23.1) |  |
 No | 526 | 186 (72.9) | 153 (78.5) | 142 (75.5) | 45 (76.3) |  | 186 (72.9) | 340 (76.9) |  |
EBV-DNA (copies/mL)a | Â | Â | Â | Â | Â | 0.435 | Â | Â | 0.829 |
 <1530 | 85 | 31 (50.8) | 20 (46.5) | 22 (44.9) | 12 (66.7) |  | 31 (50.8) | 54 (49.1) |  |
 ≥1530 | 86 | 30 (49.2) | 23 (53.5) | 27 (55.1) | 6 (33.3) |  | 30 (49.2) | 56 (50.9) |  |
CRP (mg/L)b | Â | Â | Â | Â | Â | 0.197 | Â | Â | 0.038 |
 ≤10 | 128 | 55 (61.1) | 26 (50.0) | 36 (46.3) | 11 (42.1) |  | 55 (61.1) | 73 (47.1) |  |
 >10 | 100 | 35 (38.9) | 26 (50.0) | 31 (53.7) | 8 (57.9) |  | 35 (38.9) | 65 (52.9) |  |
Ann Arbor stage | Â | Â | Â | Â | Â | 0.749 | Â | Â | 0.894 |
 I/II | 619 | 227 (89.0) | 173 (88.7) | 169 (89.9) | 50 (84.7) |  | 227 (89.0) | 392 (88.7) |  |
 III/IV | 78 | 28 (11.0) | 22 (11.3) | 19 (10.1) | 9 (15.3) |  | 28 (11.0) | 50 (11.3) |  |
IPI score | Â | Â | Â | Â | Â | 0.763 | Â | Â | 0.421 |
 0–1 | 597 | 222 (87.1) | 164 (84.1) | 162 (86.2) | 49 (83.1) |  | 222 (87.1) | 375 (84.8) |  |
 2–5 | 100 | 33 (12.9) | 31 (15.9) | 26 (13.8) | 10 (16.9) |  | 33 (12.9) | 67 (15.2) |  |
KPI score | Â | Â | Â | Â | Â | 0.974 | Â | Â | 0.984 |
 0–1 | 478 | 175 (68.6) | 133 (68.2) | 128 (68.1) | 42 (71.2) |  | 175 (68.6) | 303 (68.6) |  |
 2–4 | 219 | 80 (31.4) | 62 (31.8) | 60 (31.9) | 17 (28.8) |  | 80 (31.4) | 139 (31.4) |  |